Litcius/Paper detail

Meropenem Population Pharmacokinetics and Simulations in Plasma, Cerebrospinal Fluid, and Brain Tissue

Mohammad H. Al‐Shaer, Brooke Barlow, Nicole Maranchick, Miriam M. Moser, Leon Gramss, Heinz Burgmann, Valentin al Jalali, Michael Wölfl‐Duchek, Walter Jäger, Stefan Poschner, Walter Plöchl, Andrea Reinprecht, Karl Rössler, Andreas Gruber, Markus Zeitlinger, Charles A. Peloquin, Arthur Hosmann

2022Antimicrobial Agents and Chemotherapy12 citationsDOIOpen Access PDF

Abstract

, respectively. In the first 24 h, meropenem 2 g, administered every 8 h via intermittent and extended infusions achieved good target attainment in the CSF and brain, but continuous infusion (CI) was better at steady-state. Administering a 3 g loading dose (LD) followed by 8 g CI was beneficial for early target attainment. In conclusion, a meropenem PK model was developed using blood, CSF, and brain microdialysate samples. An 8 g CI may be needed for good target attainment in the CSF and brain. Giving a LD prior to the CI improved the probability of early target attainment.

Topics & Concepts

MeropenemPharmacokineticsCerebrospinal fluidPopulation pharmacokineticsMedicinePopulationPharmacologyInternal medicineAntibioticsBiologyMicrobiologyAntibiotic resistanceEnvironmental healthAntibiotics Pharmacokinetics and EfficacyDrug Transport and Resistance MechanismsEpilepsy research and treatment